COMBINATION THERAPY FOR STABLE AND LONG-TERM TRANSPLANT ENGRAFTMENT Russian patent published in 2018 - IPC A61K35/28 C12N5/783 A61P35/00 A61P37/06 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to transplantology, and can be used to treat a subject needing a non-syngeneic cell or tissue graft. Method of treatment comprises: (a) transplanting to a subject a dose of immature hematopoietic cells depleted of T cells, said immature hematopoietic cells depleted of T cells containing less than 5×10⁵ CD3⁺ cells per kg body weight of the subject, and wherein said dose comprises at least about 5×10⁶ CD34⁺ cells per kg body weight of the subject; and subsequently; (b) administering to the subject a therapeutically effective amount of cyclophosphamide, said therapeutically effective amount being 25–200 mg per kg body weight of the subject, and wherein said cyclophosphamide is administered to the subject after transplantation, thereby providing treatment to the subject. Group of inventions also relates to method for treating a subject in need of transplanting immature hematopoietic cells and to method for inducing donor-specific tolerance in a subject.

EFFECT: use of this group of inventions ensures engraftment of hematopoietic stem cells with minimal conditioning protocol and leads to induction of tolerance, as evidenced by acceptance of donor skin grafts.

26 cl, 7 dwg, 5 tbl, 5 ex